Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Apr 24, 2019 Aytu BioScience Announces Submission of ZolpiMist (TM) for Approval to Australian Therapeutic Goods Administration (TGA)
Apr 16, 2019 Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors
Mar 27, 2019 Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment
Mar 19, 2019 Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels
Mar 14, 2019 Aytu BioScience Announces Natesto(R) Presentations at Two Upcoming Scientific Conferences

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 1.96
Volume 329,562
Day Range 1.92 - 2.05
52 Week Range 0.23 - 6.96
Bid/Ask 1.96 / 2.02
Bid/Ask Size 100 X 100
Previous Close 1.91
Market Cap 24.66 million
Shares Outstanding 12.39 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -7.172500
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Feb 07, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 07, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Sep 06, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Feb 08, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director